{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"}],"units":"Participants"}],"description":"Number of patients having any adverse event.","groups":[{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression or unacceptable toxicity. Patients may be eligible for up to 1 year of additional pembrolizumab therapy if they progress after stopping pembrolizumab.\n\nPembrolizumab: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacogenomic Study: Correlative studies","id":"OG000","title":"Treatment (Pembrolizumab)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 30 days after completion of study treatment, maximum of 5 years.","title":"Incidence of Toxicities Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Participants"}